1
|
Zhang J, Li Q, Liao P, Xiao R, Zhu L, Hu Q. Calcium sensing receptor: A promising therapeutic target in pulmonary hypertension. Life Sci 2024; 340:122472. [PMID: 38290572 DOI: 10.1016/j.lfs.2024.122472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 01/24/2024] [Accepted: 01/25/2024] [Indexed: 02/01/2024]
Abstract
Pulmonary hypertension (PH) is characterized by elevation of pulmonary arterial pressure and pulmonary vascular resistance. The increased pulmonary arterial pressure and pulmonary vascular resistance due to sustained pulmonary vasoconstriction and pulmonary vascular remodeling can lead to right heart failure and eventual death. A rise in intracellular Ca2+ concentration ([Ca2+]i) and enhanced pulmonary arterial smooth muscle cells (PASMCs) proliferation contribute to pulmonary vasoconstriction and pulmonary vascular remodeling. Recent studies demonstrated that extracellular calcium sensing receptor (CaSR) as a G-protein coupled receptor participates in [Ca2+]i increase induced by hypoxia in the experimental animals of PH and in PH patients. Pharmacological blockade or gene knockout of CaSR significantly attenuates the development of PH. This review will aim to discuss and update the pathogenicity of CaSR attributed to onset and progression in PH.
Collapse
Affiliation(s)
- Jiwei Zhang
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qinli Li
- Department of Clinical Laboratory Medicine, People's Hospital of Dongxihu District Wuhan City and Union Dongxihu Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Pu Liao
- Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Rui Xiao
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Liping Zhu
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qinghua Hu
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| |
Collapse
|
2
|
Wang H, Yu W, Wang Y, Wu R, Dai Y, Deng Y, Wang S, Yuan J, Tan R. p53 contributes to cardiovascular diseases via mitochondria dysfunction: A new paradigm. Free Radic Biol Med 2023; 208:846-858. [PMID: 37776918 DOI: 10.1016/j.freeradbiomed.2023.09.036] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 09/21/2023] [Accepted: 09/28/2023] [Indexed: 10/02/2023]
Abstract
Cardiovascular diseases (CVDs) are leading causes of global mortality; however, their underlying mechanisms remain unclear. The tumor suppressor factor p53 has been extensively studied for its role in cancer and is also known to play an important role in regulating CVDs. Abnormal p53 expression levels and modifications contribute to the occurrence and development of CVDs. Additionally, mounting evidence underscores the critical involvement of mitochondrial dysfunction in CVDs. Notably, studies indicate that p53 abnormalities directly correlate with mitochondrial dysfunction and may even interact with each other. Encouragingly, small molecule inhibitors targeting p53 have exhibited remarkable effects in animal models of CVDs. Moreover, therapeutic strategies aimed at mitochondrial-related molecules and mitochondrial replacement therapy have demonstrated their advantageous potential. Therefore, targeting p53 or mitochondria holds immense promise as a pioneering therapeutic approach for combating CVDs. In this comprehensive review, we delve into the mechanisms how p53 influences mitochondrial dysfunction, including energy metabolism, mitochondrial oxidative stress, mitochondria-induced apoptosis, mitochondrial autophagy, and mitochondrial dynamics, in various CVDs. Furthermore, we summarize and discuss the potential significance of targeting p53 or mitochondria in the treatment of CVDs.
Collapse
Affiliation(s)
- Hao Wang
- School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, China
| | - Wei Yu
- School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, China
| | - Yibo Wang
- School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, China
| | - Ruihao Wu
- School of Clinical Medicine, Xuzhou Medical University, Xuzhou, 221004, China
| | - Yifei Dai
- School of Stomatology, Xuzhou Medical University, Xuzhou, 221004, China
| | - Ye Deng
- School of Stomatology, Xuzhou Medical University, Xuzhou, 221004, China
| | - Shijun Wang
- Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200433, China.
| | - Jinxiang Yuan
- The Collaborative Innovation Center, Jining Medical University, Jining, 272000, China.
| | - Rubin Tan
- Department of Physiology, Basic Medical School, Xuzhou Medical University, Xuzhou, 221004, China.
| |
Collapse
|
3
|
Sweetat S, Nitzan K, Suissa N, Haimovich Y, Lichtenstein M, Zabit S, Benhamron S, Akarieh K, Mishra K, Barasch D, Saada A, Ziv T, Kakhlon O, Lorberboum-Galski H, Rosenmann H. The Beneficial Effect of Mitochondrial Transfer Therapy in 5XFAD Mice via Liver–Serum–Brain Response. Cells 2023; 12:cells12071006. [PMID: 37048079 PMCID: PMC10093713 DOI: 10.3390/cells12071006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 03/15/2023] [Accepted: 03/21/2023] [Indexed: 03/29/2023] Open
Abstract
We recently reported the benefit of the IV transferring of active exogenous mitochondria in a short-term pharmacological AD (Alzheimer’s disease) model. We have now explored the efficacy of mitochondrial transfer in 5XFAD transgenic mice, aiming to explore the underlying mechanism by which the IV-injected mitochondria affect the diseased brain. Mitochondrial transfer in 5XFAD ameliorated cognitive impairment, amyloid burden, and mitochondrial dysfunction. Exogenously injected mitochondria were detected in the liver but not in the brain. We detected alterations in brain proteome, implicating synapse-related processes, ubiquitination/proteasome-related processes, phagocytosis, and mitochondria-related factors, which may lead to the amelioration of disease. These changes were accompanied by proteome/metabolome alterations in the liver, including pathways of glucose, glutathione, amino acids, biogenic amines, and sphingolipids. Altered liver metabolites were also detected in the serum of the treated mice, particularly metabolites that are known to affect neurodegenerative processes, such as carnosine, putrescine, C24:1-OH sphingomyelin, and amino acids, which serve as neurotransmitters or their precursors. Our results suggest that the beneficial effect of mitochondrial transfer in the 5XFAD mice is mediated by metabolic signaling from the liver via the serum to the brain, where it induces protective effects. The high efficacy of the mitochondrial transfer may offer a novel AD therapy.
Collapse
|
4
|
Yang J, Chen S, Duan F, Wang X, Zhang X, Lian B, Kou M, Chiang Z, Li Z, Lian Q. Mitochondrial Cardiomyopathy: Molecular Epidemiology, Diagnosis, Models, and Therapeutic Management. Cells 2022; 11:cells11213511. [PMID: 36359908 PMCID: PMC9655095 DOI: 10.3390/cells11213511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 10/15/2022] [Accepted: 11/02/2022] [Indexed: 11/09/2022] Open
Abstract
Mitochondrial cardiomyopathy (MCM) is characterized by abnormal heart-muscle structure and function, caused by mutations in the nuclear genome or mitochondrial DNA. The heterogeneity of gene mutations and various clinical presentations in patients with cardiomyopathy make its diagnosis, molecular mechanism, and therapeutics great challenges. This review describes the molecular epidemiology of MCM and its clinical features, reviews the promising diagnostic tests applied for mitochondrial diseases and cardiomyopathies, and details the animal and cellular models used for modeling cardiomyopathy and to investigate disease pathogenesis in a controlled in vitro environment. It also discusses the emerging therapeutics tested in pre-clinical and clinical studies of cardiac regeneration.
Collapse
Affiliation(s)
- Jinjuan Yang
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
| | - Shaoxiang Chen
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
| | - Fuyu Duan
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
| | - Xiuxiu Wang
- Department of Laboratory Medicine, Pingyang People’s Hospital Affiliated to Wenzhou Medical University, Wenzhou 325499, China
| | - Xiaoxian Zhang
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
| | - Boonxuan Lian
- Adelaide Medical School, University of Adelaide, 30 Frome Rd., Adelaide, SA 5000, Australia
| | - Meng Kou
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
| | - Zhixin Chiang
- Department of Allied Health Science Faculty of Science, Tunku Abdul Rahman University, Ipoh 31900, Malaysia
| | - Ziyue Li
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
| | - Qizhou Lian
- Cord Blood Bank Centre, Guangzhou Women and Children’s Medical Centre, Guangzhou Medical University, Guangzhou 510180, China
- Department of Surgery, Shenzhen Hong Kong University Hospital, Shenzhen 518053, China
- State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong 999077, China
- Correspondence: ; Tel.: +852-2831-5403
| |
Collapse
|
5
|
Xiao R, Liu J, Luo S, Yu Z, Zhang J, Lv Y, Li J, Ruiz M, Dupuis J, Hu Q, Zhu L. Orally-administrated mitochondria attenuate pulmonary hypertension with the aid of erythrocytes as carriers. Clin Transl Med 2022; 12:e1033. [PMID: 36149749 PMCID: PMC9505751 DOI: 10.1002/ctm2.1033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 08/05/2022] [Accepted: 08/09/2022] [Indexed: 11/05/2022] Open
Affiliation(s)
- Rui Xiao
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jie Liu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shengquan Luo
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zhe Yu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiwei Zhang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yankai Lv
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiansha Li
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Matthieu Ruiz
- Department of Nutrition, Université de Montréal, Montreal, Canada.,Montreal Heart Institute, Montreal, Canada
| | - Jocelyn Dupuis
- Montreal Heart Institute, Montreal, Canada.,Department of medicine, Université de Montréal, Montreal, Canada
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
6
|
Cai Z, Huang Y, He B. New Insights into Adipose Tissue Macrophages in Obesity and Insulin Resistance. Cells 2022; 11:1424. [PMID: 35563728 PMCID: PMC9104938 DOI: 10.3390/cells11091424] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 04/15/2022] [Accepted: 04/20/2022] [Indexed: 02/04/2023] Open
Abstract
Obesity has become a worldwide epidemic that poses a severe threat to human health. Evidence suggests that many obesity comorbidities, such as type 2 diabetes mellitus, steatohepatitis, and cardiovascular diseases, are related to obesity-induced chronic low-grade inflammation. Macrophages are the primary immune cells involved in obesity-associated inflammation in both mice and humans. Intensive research over the past few years has yielded tremendous progress in our understanding of the additional roles of adipose tissue macrophages (ATMs) beyond classical M1/M2 polarization in obesity and related comorbidities. In this review, we first characterize the diverse subpopulations of ATMs in the context of obesity. Furthermore, we review the recent advance on the role of the extensive crosstalk between adipocytes and ATMs in obesity. Finally, we focus on the extended crosstalk within adipose tissue between perivascular mesenchymal cells and ATMs. Understanding the pathological mechanisms that underlie obesity will be critical for the development of new intervention strategies to prevent or treat this disease and its associated co-morbidities.
Collapse
Affiliation(s)
| | | | - Ben He
- Heart Center, Shanghai Chest Hospital, Shanghai Jiaotong University, 241 Huaihai West Road, Shanghai 200030, China; (Z.C.); (Y.H.)
| |
Collapse
|
7
|
Hosseinian S, Ali Pour P, Kheradvar A. Prospects of mitochondrial transplantation in clinical medicine: aspirations and challenges. Mitochondrion 2022; 65:33-44. [DOI: 10.1016/j.mito.2022.04.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/24/2022] [Accepted: 04/27/2022] [Indexed: 12/21/2022]
|
8
|
Xiao R, Luo S, Zhang T, Lv Y, Wang T, Zhang J, Su Y, Ruiz M, Dupuis J, Zhu L, Hu Q. Peptide Blocking Self-Polymerization of Extracellular Calcium-Sensing Receptor Attenuates Hypoxia-Induced Pulmonary Hypertension. Hypertension 2021; 78:1605-1616. [PMID: 34565182 DOI: 10.1161/hypertensionaha.120.16712] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Rui Xiao
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Shengquan Luo
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Ting Zhang
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Yankai Lv
- Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.).,Department of Pathology (Y.L.), Tongji Hospital
| | - Tao Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine (T.W.), Tongji Hospital
| | | | - Yuan Su
- Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.).,Department of Respiratory and Critical Care Medicine, Union Hospital (Y.S.)
| | - Matthieu Ruiz
- Tongji Medical College, Huazhong University of Science and Technology (HUST), China; Department of Nutrition, Université de Montréal, Canada (M.R.).,Montreal Heart Institute, Canada (M.R., J.D.)
| | - Jocelyn Dupuis
- Montreal Heart Institute, Canada (M.R., J.D.).,Department of medicine, Université de Montréal, Canada (J.D.)
| | - Liping Zhu
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| | - Qinghua Hu
- From the Department of Pathophysiology, School of Basic Medicine (R.X., S.L., T.Z., L.Z., Q.H.).,Key Laboratory of Pulmonary Diseases of Ministry of Health (R.X., S.L., T.Z., Y.L., T.W., J.Z., Y.S., L.Z., Q.H.)
| |
Collapse
|
9
|
Li D, Yang S, Xing Y, Pan L, Zhao R, Zhao Y, Liu L, Wu M. Novel Insights and Current Evidence for Mechanisms of Atherosclerosis: Mitochondrial Dynamics as a Potential Therapeutic Target. Front Cell Dev Biol 2021; 9:673839. [PMID: 34307357 PMCID: PMC8293691 DOI: 10.3389/fcell.2021.673839] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 06/16/2021] [Indexed: 12/12/2022] Open
Abstract
Cardiovascular disease (CVD) is the main cause of death worldwide. Atherosclerosis is the underlying pathological basis of CVD. Mitochondrial homeostasis is maintained through the dynamic processes of fusion and fission. Mitochondria are involved in many cellular processes, such as steroid biosynthesis, calcium homeostasis, immune cell activation, redox signaling, apoptosis, and inflammation, among others. Under stress conditions, mitochondrial dynamics, mitochondrial cristae remodeling, and mitochondrial ROS (mitoROS) production increase, mitochondrial membrane potential (MMP) decreases, calcium homeostasis is imbalanced, and mitochondrial permeability transition pore open (mPTP) and release of mitochondrial DNA (mtDNA) are activated. mtDNA recognized by TLR9 can lead to NF-κB pathway activation and pro-inflammatory factor expression. At the same time, TLR9 can also activate NLRP3 inflammasomes and release interleukin, an event that eventually leads to tissue damage and inflammatory responses. In addition, mitochondrial dysfunction may amplify the activation of NLRP3 through the production of mitochondrial ROS, which together aggravate accumulating mitochondrial damage. In addition, mtDNA defects or gene mutation can lead to mitochondrial oxidative stress. Finally, obesity, diabetes, hypertension and aging are risk factors for the progression of CVD, which are closely related to mitochondrial dynamics. Mitochondrial dynamics may represent a new target in the treatment of atherosclerosis. Antioxidants, mitochondrial inhibitors, and various new therapies to correct mitochondrial dysfunction represent a few directions for future research on therapeutic intervention and amelioration of atherosclerosis.
Collapse
Affiliation(s)
- Dan Li
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Shengjie Yang
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yanwei Xing
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Limin Pan
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Ran Zhao
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Yixi Zhao
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Longtao Liu
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Min Wu
- Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
10
|
Chernyak BV. Mitochondrial Transplantation: A Critical Analysis. BIOCHEMISTRY (MOSCOW) 2021; 85:636-641. [PMID: 32571194 DOI: 10.1134/s0006297920050132] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
"Mitochondrial transplantation" refers to a procedure for introducing isolated mitochondria into a damaged area of a heart or other organ. A considerable amount of data has been accumulated on the therapeutic effects of "mitochondrial transplantation" in animals with ischemic heart damage. In 2017, the first attempts were made to apply this procedure in a clinic. The authors of the method suggest that exogenous mitochondria penetrate into cardiomyocytes, retaining functional activity, and compensate for impaired energy output of endogenous mitochondria. This hypothesis contradicts the well-known fact of loss of mitochondrial functions in the presence of high concentrations of Ca2+, which are characteristic of the extracellular medium. This review critically considers the possible mechanisms of the therapeutic effect of "mitochondrial transplantation".
Collapse
Affiliation(s)
- B V Chernyak
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
| |
Collapse
|
11
|
Hypermethylation of mitochondrial DNA in vascular smooth muscle cells impairs cell contractility. Cell Death Dis 2020; 11:35. [PMID: 31959742 PMCID: PMC6971246 DOI: 10.1038/s41419-020-2240-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 01/08/2020] [Accepted: 01/08/2020] [Indexed: 01/26/2023]
Abstract
Vascular smooth muscle cell (SMC) from arterial stenotic-occlusive diseases is featured with deficiency in mitochondrial respiration and loss of cell contractility. However, the regulatory mechanism of mitochondrial genes and mitochondrial energy metabolism in SMC remains elusive. Here, we described that DNA methyltransferase 1 (DNMT1) translocated to the mitochondria and catalyzed D-loop methylation of mitochondrial DNA in vascular SMCs in response to platelet-derived growth factor-BB (PDGF-BB). Mitochondrial-specific expression of DNMT1 repressed mitochondrial gene expression, caused functional damage, and reduced SMC contractility. Hypermethylation of mitochondrial D-loop regions were detected in the intima-media layer of mouse carotid arteries subjected to either cessation of blood flow or mechanical endothelial injury, and also in vessel specimens from patients with carotid occlusive diseases. Likewise, the ligated mouse arteries exhibited an enhanced mitochondrial binding of DNMT1, repressed mitochondrial gene expression, defects in mitochondrial respiration, and impaired contractility. The impaired contractility of a ligated vessel could be restored by ex vivo transplantation of DNMT1-deleted mitochondria. In summary, we discovered the function of DNMT1-mediated mitochondrial D-loop methylation in the regulation of mitochondrial gene transcription. Methylation of mitochondrial D-loop in vascular SMCs contributes to impaired mitochondrial function and loss of contractile phenotype in vascular occlusive disease.
Collapse
|
12
|
Knock GA. NADPH oxidase in the vasculature: Expression, regulation and signalling pathways; role in normal cardiovascular physiology and its dysregulation in hypertension. Free Radic Biol Med 2019; 145:385-427. [PMID: 31585207 DOI: 10.1016/j.freeradbiomed.2019.09.029] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 08/29/2019] [Accepted: 09/23/2019] [Indexed: 02/06/2023]
Abstract
The last 20-25 years have seen an explosion of interest in the role of NADPH oxidase (NOX) in cardiovascular function and disease. In vascular smooth muscle and endothelium, NOX generates reactive oxygen species (ROS) that act as second messengers, contributing to the control of normal vascular function. NOX activity is altered in response to a variety of stimuli, including G-protein coupled receptor agonists, growth-factors, perfusion pressure, flow and hypoxia. NOX-derived ROS are involved in smooth muscle constriction, endothelium-dependent relaxation and smooth muscle growth, proliferation and migration, thus contributing to the fine-tuning of blood flow, arterial wall thickness and vascular resistance. Through reversible oxidative modification of target proteins, ROS regulate the activity of protein tyrosine phosphatases, kinases, G proteins, ion channels, cytoskeletal proteins and transcription factors. There is now considerable, but somewhat contradictory evidence that NOX contributes to the pathogenesis of hypertension through oxidative stress. Specific NOX isoforms have been implicated in endothelial dysfunction, hyper-contractility and vascular remodelling in various animal models of hypertension, pulmonary hypertension and pulmonary arterial hypertension, but also have potential protective effects, particularly NOX4. This review explores the multiplicity of NOX function in the healthy vasculature and the evidence for and against targeting NOX for antihypertensive therapy.
Collapse
Affiliation(s)
- Greg A Knock
- Dpt. of Inflammation Biology, School of Immunology & Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, UK.
| |
Collapse
|
13
|
Moskowitzova K, Orfany A, Liu K, Ramirez-Barbieri G, Thedsanamoorthy JK, Yao R, Guariento A, Doulamis IP, Blitzer D, Shin B, Snay ER, Inkster JAH, Iken K, Packard AB, Cowan DB, Visner GA, Del Nido PJ, McCully JD. Mitochondrial transplantation enhances murine lung viability and recovery after ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 2019; 318:L78-L88. [PMID: 31693391 PMCID: PMC6985877 DOI: 10.1152/ajplung.00221.2019] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The most common cause of acute lung injury is ischemia-reperfusion injury (IRI), during which mitochondrial damage occurs. We have previously demonstrated that mitochondrial transplantation is an efficacious therapy to replace or augment mitochondria damaged by IRI, allowing for enhanced muscle viability and function in cardiac tissue. Here, we investigate the efficacy of mitochondrial transplantation in a murine lung IRI model using male C57BL/6J mice. Transient ischemia was induced by applying a microvascular clamp on the left hilum for 2 h. Upon reperfusion mice received either vehicle or vehicle-containing mitochondria either by vascular delivery (Mito V) through the pulmonary artery or by aerosol delivery (Mito Neb) via the trachea (nebulization). Sham control mice underwent thoracotomy without hilar clamping and were ventilated for 2 h before returning to the cage. After 24 h recovery, lung mechanics were assessed and lungs were collected for analysis. Our results demonstrated that at 24 h of reperfusion, dynamic compliance and inspiratory capacity were significantly increased and resistance, tissue damping, elastance, and peak inspiratory pressure (Mito V only) were significantly decreased (P < 0.05) in Mito groups as compared with their respective vehicle groups. Neutrophil infiltration, interstitial edema, and apoptosis were significantly decreased (P < 0.05) in Mito groups as compared with vehicles. No significant differences in cytokines and chemokines between groups were shown. All lung mechanics results in Mito groups except peak inspiratory pressure in Mito Neb showed no significant differences (P > 0.05) as compared with Sham. These results conclude that mitochondrial transplantation by vascular delivery or nebulization improves lung mechanics and decreases lung tissue injury.
Collapse
Affiliation(s)
- Kamila Moskowitzova
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Arzoo Orfany
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Kaifeng Liu
- Department of Pulmonary and Respiratory Diseases, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Giovanna Ramirez-Barbieri
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Jerusha K Thedsanamoorthy
- Department of Anesthesiology, Critical Care and Pain Medicine, Harvard Medical School, Boston, Massachusetts
| | - Rouan Yao
- Department of Anesthesiology, Critical Care and Pain Medicine, Harvard Medical School, Boston, Massachusetts
| | - Alvise Guariento
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Ilias P Doulamis
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - David Blitzer
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Borami Shin
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Erin R Snay
- Department of Radiology, Division of Nuclear Medicine and Molecular imaging, Boston Children's Hospital, Boston, Massachusetts
| | - James A H Inkster
- Department of Radiology, Division of Nuclear Medicine and Molecular imaging, Boston Children's Hospital, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Khadija Iken
- Department of Pulmonary and Respiratory Diseases, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Alan B Packard
- Department of Radiology, Division of Nuclear Medicine and Molecular imaging, Boston Children's Hospital, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Douglas B Cowan
- Department of Anesthesiology, Critical Care and Pain Medicine, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Gary A Visner
- Department of Pulmonary and Respiratory Diseases, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - Pedro J Del Nido
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| | - James D McCully
- Department of Cardiac Surgery, Harvard Medical School, Boston, Massachusetts.,Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
14
|
COMP-prohibitin 2 interaction maintains mitochondrial homeostasis and controls smooth muscle cell identity. Cell Death Dis 2018; 9:676. [PMID: 29867124 PMCID: PMC5986769 DOI: 10.1038/s41419-018-0703-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 05/06/2018] [Accepted: 05/14/2018] [Indexed: 12/22/2022]
Abstract
Vascular smooth muscle cells (VSMCs) are highly phenotypically plastic, and loss of the contractile phenotype in VSMCs has been recognized at the early onset of the pathology of a variety of vascular diseases. However, the endogenous regulatory mechanism to maintain contractile phenotype in VSMCs remains elusive. Moreover, little has been known about the role of the mitochondrial bioenergetics in terms of VSMC homeostasis. Herein, we asked if glycoprotein COMP (Cartilage oligomeric matrix protein) is involved in mitochondrial bioenergetics and therefore regulates VSMCs homeostasis. By using fluorescence assay, subcellular western blot and liquid chromatography tandem mass spectrometry analysis, we found that extracellular matrix protein COMP unexpectedly localized within mitochondria. Further mitochondrial transplantation revealed that both mitochondrial and non-mitochondrial COMP maintained VSMC identity. Moreover, microarray analysis revealed that COMP deficiency impaired mitochondrial oxidative phosphorylation in VSMCs. Further study confirmed that COMP deficiency caused mitochondrial oxidative phosphorylation dysfunction accompanied by morphological abnormality. Moreover, the interactome of mitochondrial COMP revealed that COMP interacted with prohibitin 2, and COMP-prohibitin 2 interaction maintained mitochondrial homeostasis. Additionally, disruption of COMP-prohibitin 2 interaction caused VSMC dedifferentiation in vitro and enhanced the neointima formation post rat carotid artery injury in vivo. In conclusion, COMP-prohibitin 2 interaction in mitochondria plays an important role in maintaining the contractile phenotype of VSMCs by regulating mitochondrial oxidative phosphorylation. Maintaining the homeostasis of mitochondrial respiration through COMP-prohibitin 2 interaction may shed light on prevention of vascular disease.
Collapse
|
15
|
Shi X, Bai H, Zhao M, Li X, Sun X, Jiang H, Fu A. Treatment of acetaminophen-induced liver injury with exogenous mitochondria in mice. Transl Res 2018; 196:31-41. [PMID: 29548626 DOI: 10.1016/j.trsl.2018.02.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2017] [Revised: 02/20/2018] [Accepted: 02/20/2018] [Indexed: 01/07/2023]
Abstract
Drug-induced liver injury shares a common feature of mitochondrial dysfunction. Mitochondrial therapy (mitotherapy), which replaces malfunctional mitochondria with functional exogenous mitochondria, may be a fundamental approach for treating drug-mediated hepatotoxicity. Here, we suggested that mitochondria isolated from human hepatoma cell could be used to treat acetaminophen (APAP)-induced liver injury in mice. When the mitochondria were added into the cell media, they could enter primarily cultured mouse hepatocyte. When the mitochondria were intravenously injected into mice, they distribute in several tissues, including liver. In the model mice of APAP-induced liver injury, mitochondria treatment increased hepatocyte energy supply, reduced oxidation stress, and consequently ameliorated tissue injury. The study suggests that exogenous mitochondria could be an effective therapeutic strategy in treating APAP-induced liver injury.
Collapse
Affiliation(s)
- Xianxun Shi
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China
| | - Huiyuan Bai
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China
| | - Ming Zhao
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China
| | - Xiaorong Li
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China
| | - Xianchao Sun
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China
| | - Hongbo Jiang
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China
| | - Ailing Fu
- School of Pharmaceutical Sciences, Southwest University, Chongqing, China.
| |
Collapse
|
16
|
Zhu L, Zhang J, Zhou J, Lu Y, Huang S, Xiao R, Yu X, Zeng X, Liu B, Liu F, Sun M, Dai M, Hao Q, Li J, Wang T, Li T, Hu Q. Mitochondrial transplantation attenuates hypoxic pulmonary hypertension. Oncotarget 2018; 7:48925-48940. [PMID: 27419637 PMCID: PMC5226481 DOI: 10.18632/oncotarget.10596] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2016] [Accepted: 06/30/2016] [Indexed: 01/01/2023] Open
Abstract
Mitochondria are essential for the onset of hypoxia-induced pulmonary vasoconstriction and pulmonary vascular-remodeling, two major aspects underlying the development of pulmonary hypertension, an incurable disease. However, hypoxia induces relaxation of systemic arteries such as femoral arteries and mitochondrial heterogeneity controls the distinct responses of pulmonary versus femoral artery smooth muscle cells to hypoxia in vitro. The aim of this study was to determine whether mitochondrial heterogeneity can be experimentally exploited in vivo for a potential treatment against pulmonary hypertension. The intact mitochondria were transplanted into Sprague-Dawley rat pulmonary artery smooth muscle cells in vivo via intravenous administration. The immune-florescent staining and ultrastructural examinations on pulmonary arteries confirmed the intracellular distribution of exogenous mitochondria and revealed the possible mitochondrial transfer from pulmonary artery endothelial cells into smooth muscle cells in part through their intercellular space and intercellular junctions. The transplantation of mitochondria derived from femoral artery smooth muscle cells inhibited acute hypoxia-triggered pulmonary vasoconstriction, attenuated chronic hypoxia-induced pulmonary vascular remodeling, and thus prevented the development of pulmonary hypertension or cured the established pulmonary hypertension in rats exposed to chronic hypoxia. Our findings suggest that mitochondrial transplantation possesses potential implications for exploring a novel therapeutic and preventive strategy against pulmonary hypertension.
Collapse
Affiliation(s)
- Liping Zhu
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Jiwei Zhang
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Department of Pathology, Union Hospital, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Juan Zhou
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Current address: Department of Clinical Laboratory of Xuzhou Central Hospital, Xuzhou, China
| | - Yankai Lu
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Songling Huang
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Rui Xiao
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Xiangyuan Yu
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Xianqin Zeng
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Bingxun Liu
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Fangbo Liu
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Mengxiang Sun
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Mao Dai
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Qiang Hao
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Jiansha Li
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Department of Pathology, Tongji Hospital, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Tao Wang
- Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| | - Tongfei Li
- Department of Pathology, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China
| | - Qinghua Hu
- Department of Pathophysiology, School of Basic Medicine, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China.,Key Laboratory of Pulmonary Diseases of Ministry of Health, Huazhong University of Science and Technology (HUST), Wuhan, Hubei, China
| |
Collapse
|
17
|
Zhu L, Lu Y, Zhang J, Hu Q. Subcellular Redox Signaling. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 967:385-398. [DOI: 10.1007/978-3-319-63245-2_25] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
18
|
Zeng X, Zhu L, Xiao R, Liu B, Sun M, Liu F, Hao Q, Lu Y, Zhang J, Li J, Wang T, Wei X, Hu Q. Hypoxia-Induced Mitogenic Factor Acts as a Nonclassical Ligand of Calcium-Sensing Receptor, Therapeutically Exploitable for Intermittent Hypoxia-Induced Pulmonary Hypertension. Hypertension 2017; 69:844-854. [PMID: 28348014 DOI: 10.1161/hypertensionaha.116.08743] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 12/03/2016] [Accepted: 02/26/2017] [Indexed: 11/16/2022]
Abstract
Hypoxia-induced mitogenic factor (HIMF) is an inflammatory cytokine playing important role(s) in the development of hypoxic pulmonary hypertension. The molecular target mediating HIMF-stimulated downstream events remains unclear. The coimmunoprecipitation screen identified extracellular calcium-sensing receptor (CaSR) as the binding partner for HIMF in pulmonary artery smooth muscle cells. The yeast 2-hybrid assay then revealed the binding of HIMF to the intracellular, not the extracellular, domain of extracellular CaSR. The binding of HIMF enhanced the activity of extracellular CaSR and mediated hypoxia-evoked proliferation of pulmonary artery smooth cells and the development of pulmonary vascular remodeling and pulmonary hypertension, all of which was specifically attenuated by a synthesized membrane-permeable peptide flanking the core amino acids of the intracellular binding domain of extracellular CaSR. Thus, HIMF induces pulmonary hypertension as a nonclassical ligand of extracellular CaSR, and the binding motif of extracellular CaSR can be therapeutically exploitable.
Collapse
Affiliation(s)
- Xianqin Zeng
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Liping Zhu
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Rui Xiao
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Bingxun Liu
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Mengxiang Sun
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Fangbo Liu
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Qiang Hao
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Yankai Lu
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Jiwei Zhang
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Jiansha Li
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Tao Wang
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Xiang Wei
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China
| | - Qinghua Hu
- From the Department of Pathophysiology, School of Basic Medicine (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Q. Hu), Key Laboratory of Pulmonary Diseases of Ministry of Health (X.Z., L.Z., R.X., B.L., M.S., F.L., Q. Hao, Y.L., J.Z., J.L., T.W., Q. Hu), Department of Pathology, Tongji Hospital (Y.L., J.L.), Department of Pathology, Union Hospital (J.Z.), Department of Respiratory and Critical Care Medicine (T.W.), and Department of Cardiothoracic and Vascular Surgery, Tongji Hospital (X.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
| |
Collapse
|
19
|
Sightings, edited by Erik Swenson and Peter Bärtsch. High Alt Med Biol 2016; 17:143-146. [PMID: 27689469 DOI: 10.1089/ham.2016.29013.stg] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|